Literature DB >> 23750038

Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.

Michael Stotz1, Florian Eisner, Joanna Szkandera, Gudrun Absenger, Peter Kornprat, Carolin Lackner, Hellmut Samonigg, Armin Gerger, Martin Pichler.   

Abstract

AIMS: Pancreatic cancer (PC) is a heterogeneous disease in terms of histological and molecular subtypes. The aim of this study was to evaluate the prognostic impact of different histological subtypes on cancer-specific survival (CSS) in a large single-centre Middle European cohort.
METHODS: We retrospectively studied the records of 400 consecutive PC patients who were treated from 2004 to 2010 at a single tertiary academic centre. The association of histological subtypes and parameters such as tumour stage, tumour grade, levels of tumour markers carcinoembryonic antigen and CA19-9 at diagnosis, was studied. CSS was calculated using the Kaplan-Meier method, and the influence of each parameter on CSS was assessed with univariate and multivariable Cox proportional models.
RESULTS: The survival time was significantly shorter in the ductal adenocarcinoma and acinar histological subtypes compared to neuroendocrine differentiation (p<0.001). No survival difference was observed between ductal adenocarcinomas and patients with a histological variant of ductal adenocarcinoma, namely, mucinous non-cystic adenocarcinoma (p=0.7). In multivariable analysis, ductal adenocarcinoma (HR=3.1, CI 1.6 to 6.1, p=0.001) and acinar carcinoma (HR=3.2, CI 1.3 to 8.5, p=0.016) were identified as independent predictors for CSS.
CONCLUSIONS: Our findings suggest that the main histological subtype is an independent predictor of CSS in patients with PC. Thus, our data underline the importance of routine assessment of histological type in PC for individual risk assessment. However, no clinical rationale for the subdivision of ductal adenocarcinoma and mucinous non-cystic adenocarcinoma can be supported by our study.

Entities:  

Keywords:  Neuroendocrine Tumours; Pancreatic Cancer; Surgical Pathology

Mesh:

Substances:

Year:  2013        PMID: 23750038     DOI: 10.1136/jclinpath-2012-201394

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma.

Authors:  De-Jun Liu; Yue-Xia Xie; Xiao-Xing Liu; Yan-Miao Huo; Min-Wei Yang; Xue-Liang Fu; Wei Liu; Jian-Yu Yang; Jiao Li; Rong Hua; Pei-Feng Liu; Yong-Wei Sun; Jun-Feng Zhang
Journal:  Cell Cycle       Date:  2017-07-27       Impact factor: 4.534

2.  Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients.

Authors:  Michael Stotz; Joanna Szkandera; Julia Seidel; Tatjana Stojakovic; Hellmut Samonigg; Daniel Reitz; Thomas Gary; Peter Kornprat; Renate Schaberl-Moser; Gerald Hoefler; Armin Gerger; Martin Pichler
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

3.  Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.

Authors:  Meng Zhou; Zhiyong Diao; Xiaolong Yue; Yang Chen; Hengqiang Zhao; Liang Cheng; Jie Sun
Journal:  Oncotarget       Date:  2016-08-30

4.  Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.

Authors:  Eva Asamer; Joanna Szkandera; Paul Gibiser; Anna Lena Lembeck; Tatjana Stojakovic; Peter Kornprat; Caroline Lackner; Thomas Winder; Konstantin Schlick; Herbert Stöger; Armin Gerger; Martin Pichler; Michael Stotz
Journal:  Wien Klin Wochenschr       Date:  2018-08-21       Impact factor: 1.704

5.  Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.

Authors:  Xiwen Liao; Xiangkun Wang; Ketuan Huang; Chengkun Yang; Tingdong Yu; Chuangye Han; Guangzhi Zhu; Hao Su; Rui Huang; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-08-10       Impact factor: 3.989

6.  The Development of a Prediction Model Based on Random Survival Forest for the Postoperative Prognosis of Pancreatic Cancer: A SEER-Based Study.

Authors:  Jiaxi Lin; Minyue Yin; Lu Liu; Jingwen Gao; Chenyan Yu; Xiaolin Liu; Chunfang Xu; Jinzhou Zhu
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

7.  Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma.

Authors:  Wael Al-Zoughbi; Silvia Schauer; Martin Pichler; Gerald Hoefler
Journal:  Pathobiology       Date:  2018-09-18       Impact factor: 3.916

8.  External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

Authors:  Joanna Szkandera; Michael Stotz; Florian Eisner; Gudrun Absenger; Tatjana Stojakovic; Hellmut Samonigg; Peter Kornprat; Renate Schaberl-Moser; Wael Alzoughbi; Anna Lena Ress; Friederike Sophia Seggewies; Armin Gerger; Gerald Hoefler; Martin Pichler
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.